We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-4.98%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.46B
AUM Growth
-$155M
Cap. Flow
+$105M
Cap. Flow %
3.02%
Top 10 Hldgs %
66.74%
Holding
34
New
4
Increased
12
Reduced
7
Closed
2
Avg Time Held
11.7 quarters
Top 10 Avg Time Held
12.8 quarters
Top 20 Avg Time Held
13.4 quarters

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$40.4M
2
ESPR icon
Esperion Therapeutics
ESPR
+$38.9M
3
TSRO
TESARO, Inc.
TSRO
+$38.7M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$23.2M
5
EXEL icon
Exelixis
EXEL
+$21.9M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$49.8M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$29.4M
3
GILD icon
Gilead Sciences
GILD
+$21.2M
4
PRTA icon
Prothena Corp
PRTA
+$14.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IONS icon
1
Ionis Pharmaceuticals
IONS
$7.52B
$361M 10.43%
8,666,334
+150,000
+2% +$6.65M
2013 Q2
20 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$14.5B
$326M 9.41%
3,317,753
-85,000
-2% -$7.61M
2013 Q3
19 quarters
CELG
3
DELISTED
Celgene Corp
CELG
$264M 7.62%
3,324,298
– –
2013 Q2
20 quarters
INCY icon
4
Incyte
INCY
$22.9B
$252M 7.27%
3,758,322
+60,000
+2% +$4.1M
2013 Q2
20 quarters
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$129B
$238M 6.87%
1,400,445
-75,000
-5% -$11.6M
2013 Q2
20 quarters
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.9B
$185M 5.35%
2,197,931
-337,322
-13% -$29.4M
2014 Q2
16 quarters
RDUS icon
7
DELISTED
Radius Health, Inc.
RDUS
$183M 5.28%
6,200,913
+347,114
+6% +$11M
2014 Q2
16 quarters
GILD icon
8
Gilead Sciences
GILD
$187B
$168M 4.86%
2,374,596
-300,000
-11% -$21.2M
2013 Q2
20 quarters
SAGE icon
9
DELISTED
Sage Therapeutics
SAGE
$168M 4.84%
1,071,373
+68,934
+7% +$10.8M
2015 Q4
10 quarters
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$167M 4.82%
1,344,428
-50,000
-4% -$5.84M
2013 Q2
20 quarters
HALO icon
11
Halozyme
HALO
$12.5B
$139M 4.02%
8,247,860
-272,277
-3% -$5.15M
2013 Q2
20 quarters
ESPR icon
12
DELISTED
Esperion Therapeutics
ESPR
$125M 3.6%
3,182,964
+770,000
+32% +$38.9M
2015 Q3
11 quarters
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$31.1B
$112M 3.24%
1,140,538
+129,200
+13% +$12.8M
2013 Q2
20 quarters
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$108M 3.12%
2,426,802
+797,059
+49% +$38.7M
2013 Q3
19 quarters
REGN icon
15
Regeneron Pharmaceuticals
REGN
$76.9B
$93.1M 2.69%
270,000
-10,000
-4% -$3.13M
2013 Q3
19 quarters
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
$80.2M 2.32%
3,507,882
– –
2016 Q4
6 quarters
AKCA
17
DELISTED
Akcea Therapeutics Inc
AKCA
$58.9M 1.7%
2,484,071
+94,500
+4% +$2.26M
2017 Q4
2 quarters
MGNX icon
18
MacroGenics
MGNX
$238M
$54.9M 1.59%
2,660,412
+60,000
+2% +$1.35M
2016 Q2
8 quarters
VYGR icon
19
Voyager Therapeutics
VYGR
$151M
$49.5M 1.43%
2,532,641
+540,000
+27% +$10.7M
2017 Q4
2 quarters
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$45.8M 1.32%
545,719
– –
2015 Q1
13 quarters
WVE icon
21
Wave Life Sciences
WVE
$682M
$43.5M 1.26%
1,137,885
+241,789
+27% +$10.4M
2017 Q4
2 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$38.9M 1.12%
2,200,000
– –
2016 Q2
8 quarters
ARGX icon
23
argenx
ARGX
$51.9B
$37.2M 1.07%
449,049
+52,230
+13% +$4.67M
2018 Q1
1 quarter
ALDR
24
DELISTED
Alder Biopharmaceuticals
ALDR
$35.8M 1.03%
2,266,008
– –
2015 Q2
12 quarters
NKTR icon
25
Nektar Therapeutics
NKTR
$1.41B
$25.6M 0.74%
+35,000
New +$40.4M
2018 Q2
0 quarters
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2018 Portfolio in Review

As of Q2 2018, BB Biotech held 34 positions worth $3.46B, down 4.3% from $3.62B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

BB Biotech deployed $105M of net new capital in Q2 2018, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Nektar Therapeutics: 35,000 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $29.4M trimmed.

  • BB Biotech's largest Q2 2018 buy was Nektar Therapeutics: 35,000 shares worth $25.6M.
  • BB Biotech added most to Esperion Therapeutics in Q2 2018, an estimated $38.9M increase.
  • BB Biotech's biggest Q2 2018 reduction was Agios Pharmaceuticals, cutting an estimated $29.4M.
  • BB Biotech fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $49.8M.
  • BB Biotech's ten largest holdings make up 67% of its $3.46B portfolio in Q2 2018.
  • BB Biotech opened 4 new positions and closed 2 in Q2 2018.
  • BB Biotech's portfolio value fell 4.3% quarter-over-quarter to $3.46B.

Based on BB Biotech's 13F filing for Q2 2018, filed 9 Aug 2018.